|
ACCEPT-D
Aspirin and simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes
Ongoing trial
 |
Author(s) |
De Berardis G, Sacco M, Evangelista V, Filippi A, Giorda CB, Tognoni G, Valentini U, Nicolucci A, ACCEPT-D Study Group |
 |
Title(s) |
Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins |
|
Reference(s) |
Trials 2007;8:21–9 |
|
Disease |
Cardiovascular disease, diabetes mellitus |
|
Purpose |
To evaluate the efficacy of ASA in the primary prevention of major cardiovascular events in patients with diabetes |
|
Study design |
Randomised, open, blinded-endpoint |
|
Follow-up |
515 first cardiovascular events (expected 5 years) |
|
Patients |
Aim 5170 patients, aged ≥ 50 years, with type 1 or type 2 diabetes, already treated with or candidate for treatment with statins, LDL cholesterol ≥ 100 mg/dl and no clinical evidence of cardiovascular disease |
|
Treatment regimen |
ASA, 100 mg/day, plus simvastatin, starting dose 20 mg/day, or simvastatin alone, starting dose 20 mg/day. Simvastatin may be increased to 40 mg/day if LDL cholesterol ≥ 100 mg/dl after 3 months |
|
Results |
Not yet available |
|
|
|
